Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
230 stopped studies mapped to Breast Carcinoma by Gene Expression Profile and descendants · 97% state a reason
Over the 230 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02457910 | Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive… | Phase 1 / Phase 2 | terminated | May 29, 2015 | Vanderbilt-Ingram Cancer Center | Interim analysis - toxicity | Safety / toxicity |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With… | Phase 1 | terminated | Aug 19, 2019 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab. | Other (stated, no rule matched) |
| NCT05091528 | A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies… | Phase 1 / Phase 2 | terminated | Oct 25, 2021 | Silverback Therapeutics | Sponsor decision based on strategic re-alignment | Sponsor / business decision |
| NCT03674242 | Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the… | Phase 2 / Phase 3 | terminated | Sep 17, 2018 | ERYtech Pharma | sponsor decision | Sponsor / business decision |
| NCT05227131 | Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer(MARGARET) | Phase 2 | withdrawn | Feb 7, 2022 | MedSIR | Funder decided to not continue the study | Other (stated, no rule matched) |
| NCT04512261 | TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With…(TOPAZ) | Phase 1 / Phase 2 | withdrawn | Aug 13, 2020 | Reva Basho | Study withdrawn due to change in treatment landscape for HER2+ metastatic breast cancer. | Other (stated, no rule matched) |
| NCT02720185 | Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With… | Phase 2 | terminated | Mar 25, 2016 | University of Wisconsin, Madison | Study terminated early due to COVID-19 related slow enrollment and funding | COVID-19 / pandemic |
| NCT04178460 | A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid… | Phase 1 | terminated | Nov 26, 2019 | Zai Lab (Shanghai) Co., Ltd. | This termination decision is a business decision and is not due to any safety concerns. | Safety / toxicity |
| NCT04351230 | T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast… | Phase 2 | withdrawn | Apr 17, 2020 | Academic and Community Cancer Research United | There are no patients enrolled on this study and all efforts are being discontinued | Enrollment / accrual |
| NCT01234532 | Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed…(0927GCC) | Phase 2 | terminated | Nov 4, 2010 | University of Maryland, Baltimore | low accrual | Enrollment / accrual |
| NCT03630809 | Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1 | Phase 2 | terminated | Aug 15, 2018 | H. Lee Moffitt Cancer Center and Research Institute | Quality of the data originating from prior versions of the protocol has been affected by protocol… | COVID-19 / pandemic |
| NCT05234606 | A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1… | Phase 1 / Phase 2 | withdrawn | Feb 10, 2022 | Silverback Therapeutics | Sponsor decision based on strategic re-alignment | Sponsor / business decision |
| NCT02978716 | Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin… | Phase 2 | terminated | Dec 1, 2016 | G1 Therapeutics, Inc. | Primary Analysis and survival follow up completed per protocol. Not stopped due to safety concerns | Safety / toxicity |
| NCT02427581 | Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine… | Phase 1 | withdrawn | Apr 28, 2015 | Washington University School of Medicine | Drugs not available | Other (stated, no rule matched) |
| NCT03733119 | ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative… | Phase 2 | terminated | Nov 7, 2018 | University of Wisconsin, Madison | Slow accrual | Enrollment / accrual |
| NCT03619044 | The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor…(REVER) | N/A | terminated | Aug 7, 2018 | Institut Claudius Regaud | Slow recruitment rate | Enrollment / accrual |
| NCT05008510 | P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab…(VERU-111) | Phase 2 | withdrawn | Aug 17, 2021 | Veru Inc. | Decided to halt and will potentially reopen in the future. | Other (stated, no rule matched) |
| NCT04296942 | BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast… | Phase 1 | terminated | Mar 5, 2020 | National Cancer Institute (NCI) | One participant was accrued, and the study was stopped due to new safety data from the company for… | Safety / toxicity |
| NCT03184558 | Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC | Phase 2 | terminated | Jun 12, 2017 | BerGenBio ASA | Based on planned futility assessment | Efficacy / futility |
| NCT03634150 | Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer… | Phase 1 / Phase 2 | withdrawn | Aug 16, 2018 | Immune System Key Ltd | Patients were screened but not enrolled | Enrollment / accrual |
| NCT01957514 | Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative…(ITOMIC) | — | terminated | Oct 8, 2013 | University of Washington | Terminated due to loss of funding. | Funding |
| NCT03894007 | Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2…(PREDIXIIHER2) | Phase 2 | terminated | Mar 28, 2019 | Renske Altena | Security and effect data from another ongoing study. | Other (stated, no rule matched) |
| NCT02984683 | Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive… | Phase 2 | terminated | Dec 7, 2016 | Sanofi | Study discontinued considering the limited clinical benefit combined with a higher than expected… | Other (stated, no rule matched) |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | Phase 1 | terminated | Sep 23, 2019 | Eli Lilly and Company | Study terminated due to strategic business decision by Eli Lilly and Company. | Sponsor / business decision |
| NCT03872505 | Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple…(PANDoRA) | Phase 2 | withdrawn | Mar 13, 2019 | Cedars-Sinai Medical Center | lack of funding | Funding |
| NCT02161679 | Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With… | Phase 2 | withdrawn | Jun 12, 2014 | Gilead Sciences | FDA asked to administratively split from IND115621- to open a new IND you need to file a protocol… | Other (stated, no rule matched) |
| NCT03186937 | A Window of Opportunity Study of Methionine Deprivation in Triple Negative Breast Cancer | Phase 2 | terminated | Jun 14, 2017 | University of Wisconsin, Madison | funding and slow enrollment | Enrollment / accrual |
| NCT04067102 | Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for… | N/A | withdrawn | Aug 26, 2019 | Hebei Medical University Fourth Hospital | No patients recruited | Enrollment / accrual |
| NCT04250818 | Predicting Response of Metastatic Triple Negative Breast Cancer to Immunotherapy Based on… | — | suspended | Jan 31, 2020 | Texas Tech University Health Sciences Center, El Paso | PI is moving to a new institution | Other (stated, no rule matched) |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in… | Phase 1 / Phase 2 | withdrawn | Jul 9, 2020 | NKGen Biotech, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT02038699 | A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer | Phase 1 / Phase 2 | withdrawn | Jan 16, 2014 | Jazz Pharmaceuticals | Protocol not activated. | Other (stated, no rule matched) |
| NCT03244358 | Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer | Phase 2 | terminated | Aug 9, 2017 | Sun Yat-sen University | Difficulty accruing subjects the study accrual was closed | Enrollment / accrual |
| NCT03055312 | Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative…(SYSUCC-007) | Phase 3 | terminated | Feb 16, 2017 | Sun Yat-sen University | not stated | Not stated |
| NCT02698176 | A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced… | Phase 1 | terminated | Mar 3, 2016 | Merck Sharp & Dohme LLC | This study was terminated due to limited efficacy and not due to safety reasons. | Safety / toxicity |
| NCT02993094 | Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced… | Phase 1 / Phase 2 | terminated | Dec 15, 2016 | Arbeitsgemeinschaft medikamentoese Tumortherapie | Due to slow recruitment, the study had to be terminated prematurely. | Enrollment / accrual |
| NCT02368691 | Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple… | Phase 2 | terminated | Feb 23, 2015 | GTx | Lack of Efficacy | Efficacy / futility |
| NCT03292172 | A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and… | Phase 1 | terminated | Sep 25, 2017 | Hoffmann-La Roche | Portfolio prioritization | Sponsor / business decision |
| NCT04142554 | Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer(LCCC1820) | Phase 1 | withdrawn | Oct 29, 2019 | UNC Lineberger Comprehensive Cancer Center | Funding withdrawn from funding source. | Funding |
| NCT01745367 | Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic…(BATON-BC) | Phase 2 | terminated | Dec 10, 2012 | AVEO Pharmaceuticals, Inc. | low enrollment | Enrollment / accrual |
| NCT02095210 | HER2 PET Imaging in Breast Cancer Patients Using [68GA]ABY-025 | Phase 1 | terminated | Mar 24, 2014 | Dorte Nielsen | slow recruitment | Enrollment / accrual |
| NCT04149444 | A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer(TACTIC) | Phase 2 | withdrawn | Nov 4, 2019 | AHS Cancer Control Alberta | Sponsor withdrew support | Other (stated, no rule matched) |
| NCT03343613 | A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid… | Phase 1 | terminated | Nov 17, 2017 | Eli Lilly and Company | Study terminated due to strategic business decision by Eli Lilly and Company. | Sponsor / business decision |
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients… | Phase 1 | terminated | Oct 15, 2015 | Tocagen Inc. | Sponsor decision | Sponsor / business decision |
| NCT02003092 | RX-5902 Treatment of Subjects With Triple Negative Breast Cancer | Phase 1 / Phase 2 | terminated | Dec 6, 2013 | Rexahn Pharmaceuticals, Inc. | not stated | Not stated |
| NCT03811418 | A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab +…(ATTILA) | Phase 3 | withdrawn | Jan 22, 2019 | iOMEDICO AG | Study approved with treatment regimen based on current guidelines. However, reimbursement of IMP… | Other (stated, no rule matched) |
| NCT03777579 | A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in… | Phase 3 | suspended | Dec 17, 2018 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | trial handovered to another sponser. | Other (stated, no rule matched) |
| NCT03318562 | A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC | Phase 2 | terminated | Oct 24, 2017 | Effector Therapeutics | The study was terminated due to change in focus of the development program | Other (stated, no rule matched) |
| NCT02078752 | A Study Of PF-06647263 In Patients With Advanced Solid Tumors | Phase 1 | terminated | Mar 5, 2014 | Pfizer | The study was terminated due to a change in sponsor prioritization. | Other (stated, no rule matched) |
| NCT03644589 | Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable… | Phase 2 | withdrawn | Aug 23, 2018 | University of Washington | No participants enrolled. | Enrollment / accrual |
| NCT02299635 | A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without… | Phase 2 | terminated | Nov 24, 2014 | Pfizer | The study was terminated on June 24th, 2015 due to change in strategy of PF-03084014 development.… | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 22, 2022source: clinicaltrials